Journal: Respiratory Research

Article Title: PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs

doi: 10.1186/s12931-018-0829-5

Figure Lengend Snippet: The effect of PDGF-BB on TXB 2 and 6-keto PGF 1α. a TXB 2 -generation in dependence of the perfusion time. b Comparison of TXB 2 -generation within the groups at the same time. c 6-keto PGF 1α -generation in dependence of the perfusion time. d Comparison of 6-keto PGF 1α -generation within the groups at the same time. For all (□) control ( n = 6); (■) perfusion with PDGF-BB ( n = 6); (grey square) perfusion with imatinib / PDGF-BB ( n = 6); (□) perfusion with imatinib ( n = 6). a/c Statistics was performed by the Wilcoxon signed ranked test. b/d Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05 and ** p < 0.01

Article Snippet: Imatinib mesylate, amlodipine, fasudile, calphostin C, indomethacin, SC51322, PF04418948, L798106, L161982, GSK 1059615, AS 252424, 10-DEBC and SQ22536 were purchased from Tocris Bioscience (Ellisville, Missouri, USA).

Techniques: Comparison, Control, MANN-WHITNEY

Journal: Respiratory Research

Article Title: PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs

doi: 10.1186/s12931-018-0829-5

Figure Lengend Snippet: IPL: Effect of PDGF-BB on the pulmonary vascular tone. a Effect of PDGF-BB on P PA . b Effect of PDGF-BB on P cap. c Effect of PDGF-BB on R pre . d Effect of PDGF-BB on R post . For all: (○) control ( n = 7); (■) PDGF-BB (n = 7); (grey circle) imatinib ( n = 7); (grey square) perfused imatinib / PDGF-BB ( n = 7); (□) nebulised imatinib / PDGF-BB ( n = 6); a-d Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001. a grey square / grey circle Time point 0 ( § ) vs. 140 ( §§ ) min: p < 0.001. d grey circle Time point 0 ( § ) vs. 140 ( §§ ) min: p < 0.05

Article Snippet: Imatinib mesylate, amlodipine, fasudile, calphostin C, indomethacin, SC51322, PF04418948, L798106, L161982, GSK 1059615, AS 252424, 10-DEBC and SQ22536 were purchased from Tocris Bioscience (Ellisville, Missouri, USA).

Techniques: Control

Journal: Frontiers in Genetics

Article Title: Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation

doi: 10.3389/fgene.2022.940073

Figure Lengend Snippet: MLH1 protein levels are reduced in SW480 colorectal cells after treatment with Dasatinib and imatinib/nilotnib tyrosine kinase inhibitors. (A) Western blot analysis and quantification of MLH1 protein expression after treatment with Dasatinib in SW480 colorectal cancer cells n = 3 statistical significance was determined by unpaired t-test* p < 0.05 (B) Western blot analysis and quantification of MLH1 protein expression after treatment with imatinib (top) and nilotinib (bottom) in SW480 colorectal cancer cells n = 3 statistical significance was determined by 1-way ANOVA with Bonferroni post-test n = 3 * p < 0.05, ** p < 0.01, *** p < 0.001 (C) Target comparison of Dasatinib versus imatinib/nilotinib based on .

Article Snippet: Imatinib mesylate (imatinib) was obtained from Tocris Biosciences; 10 mM stock was prepared in dimethylsulfoxide (DMSO) (Fisher Scientific) and stored at −20°C.

Techniques: Western Blot, Expressing, Comparison

Journal: Frontiers in Genetics

Article Title: Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation

doi: 10.3389/fgene.2022.940073

Figure Lengend Snippet: MLH1 protein levels are decreased and MMR function inhibited in HEK293 cells after treatment with tyrosine kinase inhibitors. (A) Western blot analysis and quantification of MLH1 protein expression after treatment with imatinib (top) and nilotinib (bottom) in HEK293 cells statistical significance determined by 1-way ANOVA with Bonferroni post-test n = 3 * p < 0.05 (B) Treatment with imatinib or nilotinib alone does not significantly affect cell viability in HEK293 cells measured via cell count 24 h after treatment (C) Cell survival measured via viable cell count after 48-h co-treatment with imatinib/nilotinib and 6TG, statistical significance was determined by unpaired t-test n = 3 * p < 0.05.

Article Snippet: Imatinib mesylate (imatinib) was obtained from Tocris Biosciences; 10 mM stock was prepared in dimethylsulfoxide (DMSO) (Fisher Scientific) and stored at −20°C.

Techniques: Western Blot, Expressing, Cell Counting

Journal: Frontiers in Genetics

Article Title: Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation

doi: 10.3389/fgene.2022.940073

Figure Lengend Snippet: ABL1 phosphorylates MLH1. (A) MLH1 mRNA fold change with ABL1 knockdown (left) or inhibition by imatinib (right) determined by RT-qPCR n = 3 (B) MLH1 immunoprecipitation in HEK293 cells with ABL1 and MLH1 overexpressed followed by immunoblot with anti-phosphotyrosine antibody. Treatment with 5 μM nilotinib reduces the phospho-tyrosine signal associated with MLH1. (C) Kinase assay using recombinant ABL1 (25 ng) and MLH1 (100 ng) protein incubated for 15 min, followed by SDS-PAGE and immunoblot analysis indicates tyrosine phosphorylation of MLH1 only in the presence of ABL1 kinase.

Article Snippet: Imatinib mesylate (imatinib) was obtained from Tocris Biosciences; 10 mM stock was prepared in dimethylsulfoxide (DMSO) (Fisher Scientific) and stored at −20°C.

Techniques: Knockdown, Inhibition, Quantitative RT-PCR, Immunoprecipitation, Western Blot, Kinase Assay, Recombinant, Incubation, SDS Page, Phospho-proteomics

Journal: BioMed Research International

Article Title: Pharmacokinetics Interaction between Imatinib and Genistein in Rats

doi: 10.1155/2015/368976

Figure Lengend Snippet: Extracted ion chromatograms for (a) blank rat plasma, (b) blank rat plasma spiked with imatinib (10 μg/mL), N-desmethyl imatinib (0.500 μg/mL), and IS (carbamazepine), and (c) rat plasma sample after oral administration of single dosage 30 mg/kg imatinib. (1) Imatinib, (2) N-desmethyl imatinib, and (3) IS (carbamazepine).

Article Snippet: N-Desmethyl imatinib (purity > 98%) was purchased from Toronto Research Chemicals Inc. (North York, Canada).

Techniques: Clinical Proteomics

Journal: BioMed Research International

Article Title: Pharmacokinetics Interaction between Imatinib and Genistein in Rats

doi: 10.1155/2015/368976

Figure Lengend Snippet: The main pharmacokinetic parameters of imatinib in five groups ( n = 5).

Article Snippet: N-Desmethyl imatinib (purity > 98%) was purchased from Toronto Research Chemicals Inc. (North York, Canada).

Techniques:

Journal: BioMed Research International

Article Title: Pharmacokinetics Interaction between Imatinib and Genistein in Rats

doi: 10.1155/2015/368976

Figure Lengend Snippet: Mean concentration-time curve of imatinib in five groups ( n = 5).

Article Snippet: N-Desmethyl imatinib (purity > 98%) was purchased from Toronto Research Chemicals Inc. (North York, Canada).

Techniques: Concentration Assay

Journal: BioMed Research International

Article Title: Pharmacokinetics Interaction between Imatinib and Genistein in Rats

doi: 10.1155/2015/368976

Figure Lengend Snippet: Mean concentration-time curve of N-desmethyl imatinib in five groups ( n = 5).

Article Snippet: N-Desmethyl imatinib (purity > 98%) was purchased from Toronto Research Chemicals Inc. (North York, Canada).

Techniques: Concentration Assay

Journal: BioMed Research International

Article Title: Pharmacokinetics Interaction between Imatinib and Genistein in Rats

doi: 10.1155/2015/368976

Figure Lengend Snippet: The main pharmacokinetic parameters of N-desmethyl imatinib in five groups ( n = 5).

Article Snippet: N-Desmethyl imatinib (purity > 98%) was purchased from Toronto Research Chemicals Inc. (North York, Canada).

Techniques:

Journal: bioRxiv

Article Title: Loss of endothelial ALK1 signaling induces the emergence of a KIT+ angiogenic endothelial cluster driving brain arteriovenous malformations

doi: 10.1101/2025.06.05.657957

Figure Lengend Snippet: A , Experimental timeline of tamoxifen and KIT inhibitor administration in Alk1iECKO and control mice. B, D, F , CD31 immunostaining of the PNVP of P8 Alk1iECKO mice injected with imatinib ( B ), masitinib ( D ), and KIT blocking antibody ( F ), along with their corresponding vehicle controls. C, E, G , Quantification of vessel diameter in the PNVP of P8 Alk1iECKO mice injected with the indicated inhibitor. Each dot represents one mouse. Error bars represent means ± s.e.m, *P<0.05, **P<0.01, ***P<0.001, Mann-Whitney test, Welch’s t test or Unpaired t test (B, D, F) were performed.

Article Snippet: Imatinib Mesylate (100 mg/kg, Selleckchem, S1026), Masitinib Mesylate (100mg/Kg, Cerdalane, E0814), KIT blocking antibody (500 µg, InVivo MAb anti-mouse c-Kit, BioxCell, BE0293-5MG-A) were administered intraperitoneally at P6, 3 hours following tamoxifen injection, and again at P7.

Techniques: Control, Immunostaining, Injection, Blocking Assay, MANN-WHITNEY

Journal: bioRxiv

Article Title: Loss of endothelial ALK1 signaling induces the emergence of a KIT+ angiogenic endothelial cluster driving brain arteriovenous malformations

doi: 10.1101/2025.06.05.657957

Figure Lengend Snippet: A , C , CD31 immunostaining of the PNVP of P8 Alk1l/l mice injected with imatinib (A), and masitinib (C), along with their corresponding vehicle controls. B, D , Quantification of vessel diameter in the PNVP of P8 Alk1l/l mice injected with the indicated inhibitor. Each dot represents one mouse. Error bars represent means ± s.e.m, Mann-Whitney test or Unpaired t test (B, D) were performed. D , Schematic model illustrating how 48 hours of Alk1 deletion induces the emergence of angiogenic 1 ECs in both PNVP and INVP. In the PNVP, angiogenic 1 ECs further differentiate into angiogenic 2 ECs, which drive AVM formation. Both angiogenic populations express KIT, with angiogenic 2 showing stronger expression. Pharmacological inhibition of KIT effectively prevents AVM development in this model. Each dot represents one mouse.

Article Snippet: Imatinib Mesylate (100 mg/kg, Selleckchem, S1026), Masitinib Mesylate (100mg/Kg, Cerdalane, E0814), KIT blocking antibody (500 µg, InVivo MAb anti-mouse c-Kit, BioxCell, BE0293-5MG-A) were administered intraperitoneally at P6, 3 hours following tamoxifen injection, and again at P7.

Techniques: Immunostaining, Injection, MANN-WHITNEY, Expressing, Inhibition